Generalized Anxiety Disorder

Integrating CAM (Complementary and Alternative Medicine) Into Anxiety and Depression Treatment

ADAA

Philip R. Muskin, MD
Professor, Clinical Psychiatry
Columbia University Medical Center, New York

Chief of Service: Consultation-Liaison Psychiatry
New York-Presbyterian Hospital/Columbia University Medical Center

Dr. Muskin describes how complementary and alternative medicine differs from traditional therapies for anxiety and depression, when it's appropriate to employ, and effective outcomes.

Listen
“People need help. And asking for it isn’t a weakness. Admitting you need help and asking for it? That is acknowledging fear and gaining strength from it. ”

Running for Myself

A lot of things scare me. Right now, those things include my first 20-mile run of marathon training that I have this weekend and sharing this post. That’s the thing with fears, though. Embracing them usually makes you stronger.

Read

Fear of Weight Gain From SSRIs: New Podcast

1/8/2013

Dr. Beth Salcedo addresses the pros and cons of taking SSRIs (selective serotonin reuptake inhibitor) vs. weight gain and how these medications work to treat anxiety and depression. Listen to this podcast.

Fear of Weight Gain From SSRIs

ADAA

Beth Salcedo, MD
Medical Director
The Ross Center for Anxiety & Related Disorders

Assistant Clinical Professor of Psychiatry and Behavioral Sciences
The George Washington University College of Medicine and Health Sciences

Dr. Salcedo addresses the pros and cons of taking SSRIs (selective serotonin reuptake inhibitor) vs. weight gain and how these medications work to treat anxiety and depression.

Listen
“Dude, what’s your problem?”

No Shame in Having Depression and Anxiety

I have learned that anxiety and depression go hand-in-hand, and there is no shame in having either — although it’s tough for many people to get their arms around that concept. When I struggled with both in my last couple years as the Texas Rangers’ baseball play-by-play announcer, the few people in whom I confided expressed genuine shock. “Depressed? About what? You’ve got a great job! Legions of adoring fans! A wonderful family! Dude, what’s your problem?”

Read

New Podcast: Treating Coexisting Depression and Anxiety

10/1/2012

Listen to Dr. Dennis Greenberger describe the differences and similarities between symptoms of anxiety and depression, how the disorders are treated, and what patients can expect in treatment.

Mind Over Moods — Treating Coexisting Depression and Anxiety

ADAA

Dennis Greenberger, PhD
Founder and Director
Anxiety & Depression Center
Newport Beach, California

Assistant Clinical Professor
Department of Psychiatry
University of California, Irvine, College of Medicine

Dr. Greenberger describes the differences and similarities between symptoms of anxiety and depression, how the disorders are treated, and what patients can expect in treatment.

Listen

Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder

The treatment portion of this study consists of a 40 minute TMS session 5 days a week (Mon-Fri) for 6 weeks.  Other visits include an intake assessment, a pre-treatment MRI, a post-treatment assessment and MRI, and a 6 month follow up visit.  Participants are paid for both MRI visits, the post-treatment visit and the follow up visit.  Half of participants will receive real TMS, while the other half will receive sham (placebo) TMS.

Organization: 
Hartford Hospital’s Institute of Living, Yale University School of Medicine
Principal Investigator: 
Gretchen Diefenbach, PhD
Eligibility Criteria: 

Individuals with the following will be considered for this study:

 

  • Diagnosed with GAD as the principal or co-principal disorder
  • Clinical Global Impression Score ≥ 4
  • Hamilton Anxiety Rating Scale ≥ 18
  • Hamilton Rating Scale for Depression ≤ 17
  • Fluency in English
  • Capacity to understand the nature of the study and willingness to sign informed consent form
Exclusion Criteria: 

Individuals with the following will not be considered for the study:

 

  • History of epilepsy or head trauma (LOC > 5 minutes) within the past 6 months. Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis, or brain surgery
  • A review of patient medications by the study physician indicates an increased risk of seizure
  • An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency
  • Substance use disorder or post traumatic stress disorder within the past 6 months. Lifetime obsessive-compulsive disorder,bipolar disorder, psychotic disorder, mental retardation, or pervasive developmental disorder. Any psychotic features, including dementia or delirium
  • Concurrent psychotherapy and unwillingness to discontinue
  • Medication change within past 3 months
  • Current serious suicidal or homicidal ideation, and/or serious suicidal attempt within past 6 months
  • Serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study
  • Any contraindication for participation in MRI scan
Contact: 
Laura Bragdon, 860-545-7386, lbragdon@harthosp.org
Location: 
Hartford, CT
State: 
Connecticut
Study End Date: 
Sun, 2014-06-01

Locating Regions of Interest in Generalized Anxiety Disorder Using fMRI

This study consists of 2 visits: an intake assessment and an MRI visit. Participants will complete 4 tasks in the scanner in order to locate areas of the brain associated with anxiety and worry. Participants are paid for the MRI visit. 

Organization: 
Hartford Hospital’s Institute of Living, Yale University School of Medicine
Principal Investigator: 
Gretchen Diefenbach, PhD
Eligibility Criteria: 

Individuals with the following will be considered for this study:

 

  • Diagnosed with GAD as the principal or co-principal disorder
  • Clinical Global Impression Score ≥ 4
  • Hamilton Anxiety Rating Scale ≥ 18
  • Hamilton Rating Scale for Depression ≤ 17
  • Fluency in English
  • Capacity to understand the nature of the study and willingness to sign informed consent form

A control group of participants will also be enrolled who have no current (past 3 months) psychiatric disorders and no current or past psychiatric treatment.

Exclusion Criteria: 

Individuals with the following will not be considered for the study:

  • History of epilepsy or head trauma (LOC > 5 minutes) within the past 6 months. Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis, or brain surgery
  • A review of patient medications by the study physician indicates an increased risk of seizure
  • An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency
  • Substance use disorder or post traumatic stress disorder within the past 6 months. Lifetime obsessive-compulsive disorder,bipolar disorder, psychotic disorder, mental retardation, or pervasive developmental disorder. Any psychotic features, including dementia or delirium
  • Concurrent psychotherapy and unwillingness to discontinue
  • Medication change within past 3 months
  • Current serious suicidal or homicidal ideation, and/or serious suicidal attempt within past 6 months
  • Serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study
  • Any contraindication for participation in MRI scan
Contact: 
Laura Bragdon, 860-545-7386, lbragdon@harthosp.org
Location: 
Hartford, CT
State: 
Connecticut
Study End Date: 
Sun, 2014-06-01

New Podcast: Complicated Grief

8/13/2012

What's complicated about grief? Listen here, and find out how it differs from bereavement and how it's treated.

Contact ADAA

8701 Georgia Ave. #412
Silver Spring, MD 20910

240.485.1001

Contact ADAA

Request Publications

FacebookTwitterRSS

Syndicate content RSS

 

ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.